Cargando…

Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL

Chimeric antigen receptor (CAR) T cell therapy has exhibited dramatic anti-tumor efficacy in clinical trials. In this study, we reported the transcriptome profiles of bone marrow cells in four B cell acute lymphoblastic leukemia (B-ALL) patients before and after CD19-specific CAR-T therapy. CD19-CAR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qiong, Hu, Hui, Chen, Si-Yi, Liu, Chun-Jie, Hu, Fei-Fei, Yu, Jianming, Wu, Yaohui, Guo, An-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620363/ https://www.ncbi.nlm.nih.gov/pubmed/31201998 http://dx.doi.org/10.1016/j.gpb.2018.12.008

Ejemplares similares

CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities
por: Ren, Anqi, et al.
Publicado: (2023)

Systematic Transcriptome and Regulatory Network Analyses Reveal the Hypoglycemic Mechanism of Dendrobium fimbriatum
por: Zhang, Qiong, et al.
Publicado: (2019)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

CD19 CAR T-cell therapy demonstrates activity against extramedullary disease in pediatric patients with B-ALL
por: Epperly, Rebecca, et al.
Publicado: (2023)

Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL
por: Shi, Hui, et al.
Publicado: (2022)

Plasma proteomic and metabolomic signatures of B‐ALL patients during CAR‐T cell therapy
por: Wu, Jianghua, et al.
Publicado: (2023)

Transcriptome-based gene regulatory network analyses of differential cold tolerance of two tobacco cultivars
por: Luo, Zhenyu, et al.
Publicado: (2022)

Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
por: Aparicio-Pérez, Clara, et al.
Publicado: (2023)

Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy
por: Lee, Brittany M., et al.
Publicado: (2023)

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
por: Xue, YuanBo, et al.
Publicado: (2021)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway
por: Ji, Feng, et al.
Publicado: (2021)

Responder analyses for anti-amyloid immunotherapies for Alzheimer’s disease: a paradigm shift by regulatory authorities is urgently needed
por: Salemme, Simone, et al.
Publicado: (2023)

Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL
por: He, Xiaoyuan, et al.
Publicado: (2019)

Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy
por: Sheih, Alyssa, et al.
Publicado: (2020)

Enhanced tumor immunotherapy by polyfunctional CD19-CAR T cells engineered to secrete anti-CD47 single-chain variable fragment
por: Qiu, Yingqi, et al.
Publicado: (2023)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

The carP lncRNA Is a carS-Related Regulatory Element with Broad Effects on the Fusarium fujikuroi Transcriptome
por: Pardo-Medina, Javier, et al.
Publicado: (2021)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
por: Liang, Yun, et al.
Publicado: (2021)

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia
por: Tambaro, Francesco Paolo, et al.
Publicado: (2021)

Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy
por: Yang, Mingya, et al.
Publicado: (2021)

Transcriptome-wide association analyses reveal the impact of regulatory variants on rice panicle architecture and causal gene regulatory networks
por: Ming, Luchang, et al.
Publicado: (2023)

CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
por: Cui, Qingya, et al.
Publicado: (2021)

Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity
por: Wang, Zhenzhen, et al.
Publicado: (2023)

CAR Macrophages for SARS-CoV-2 Immunotherapy
por: Fu, Wenyan, et al.
Publicado: (2021)

Transcriptome Landscape Analyses of the Regulatory Network for Zygotic Embryo Development in Paeonia ostii
por: Xu, Yufeng, et al.
Publicado: (2023)

CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity
por: Bueno, Clara, et al.
Publicado: (2019)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
por: An, Lihong, et al.
Publicado: (2022)

CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
por: Arjomandnejad, Motahareh, et al.
Publicado: (2022)

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL
por: Zanetti, Samanta Romina, et al.
Publicado: (2022)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Integrated transcriptome and proteome analyses identify novel regulatory network of nucleus pulposus cells in intervertebral disc degeneration
por: Xu, Chen, et al.
Publicado: (2021)

Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells
por: Bergmann, Christina, et al.
Publicado: (2023)

Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant
por: Chen, George, et al.
Publicado: (2022)

Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy
por: Li, Xin, et al.
Publicado: (2021)

Metabolite profiling and transcriptome analyses provide insight into the regulatory network of graft incompatibility in litchi
por: Hou, Yanjie, et al.
Publicado: (2023)

A novel full-human CD22-CAR T cell therapy with potent activity against CD22(low) B-ALL
por: Tan, Yue, et al.
Publicado: (2021)

Adoptive tumour immunotherapy using human CD4+ T-cells.
por: Gold, J. E., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_2mn53nj4r8cfgf1s1oc9mpvlv4